Cells · Nov 17, 2026
Systems Immunogerontology Linking Immunosenescence and Inflammaging to Translational Interventions
By Bar-Or D, Williams J, Paredes D et al.
Immune aging involves interacting changes in host defense and inflammatory regulation rather than uniform functional decline. This narrative review examines immunosenescence and inflammaging as mutually reinforcing processes and evaluates the evidence for interventions that might interrupt their feedback. We discuss thymic involution, T-cell differentiation and dysfunction, cytomegalovirus-associated repertoire remodeling, myeloid-biased hematopoiesis, B-cell regulatory defects, and tissue- and sex-associated heterogeneity in innate immunity. Expanded consideration is given to the senescence-associated secretory phenotype, mitochondrial damage, nutrient excess, and impaired clearance as drivers of chronic inflammation. We distinguish organism-level immunosenescence from cellular senescence and separate human observations from experimental mechanisms. Inflammatory clocks, including iAge and ipAGE, and immunoglobulin G glycosylation measures offer research tools for characterizing biological heterogeneity, but their clinical decision thresholds and validity as treatment-response surrogates remain uncertain. Translational evidence ranges from small, uncontrolled senolytic and thymic-regeneration studies to randomized trials of mTOR inhibition and established efficacy of adjuvanted zoster vaccination. Negative trial findings and limitations of biomarker-based rejuvenation claims are considered. The central objective is to preserve protective immunity while reducing persistent inflammation; demonstrating durable improvements in clinical outcomes remains essential before experimental approaches can be regarded as immune rejuvenation therapies.